Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)

PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

February 10, 2020

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions
Atopic Keratoconjunctivitis
Interventions
DRUG

Dupilumab

monoclonal antibody

Trial Locations (20)

10532

RECRUITING

Gerald W. Zaidman, MD, Hawthorne

11021

COMPLETED

Northwell Health Physician Partners Ophthalmology at Great Neck, Great Neck

19004

RECRUITING

Vantage EyeCare, LLC., Bala-Cynwyd

27502

RECRUITING

NC Eye Associates, Apex

28150

RECRUITING

Vita Eye Clinic, Shelby

33021

COMPLETED

Encore Medical Research, LLC, Hollywood

37167

RECRUITING

Advancing Vision Research, LLC, Smyrna

38119

RECRUITING

Blink Research Center, Memphis

48105

WITHDRAWN

University of Michigan- Kellogg Eye Center, Ann Arbor

58103

RECRUITING

Tracie Malsom, Fargo

63017

RECRUITING

St. Louis Eye Institute, Town and Country

63131

RECRUITING

Ophthalmology Associates, St Louis

64133

RECRUITING

Silverstein Eye Centers, Kansas City

65804

RECRUITING

Mercy Clinic Eye Specialists, Springfield

66762

RECRUITING

Kannar Eye Care, Pittsburg

78681

WITHDRAWN

Eye Associates of Central Texas, Round Rock

80120

RECRUITING

Colorado Eye Consultants/Corneal Consultants of Colorado, Littleton

90013

RECRUITING

Premiere Practice Management, LLC, Los Angeles

98119

RECRUITING

Periman Eye Institute, Seattle

01810

RECRUITING

Andover Eye Associates, Andover

All Listed Sponsors
collaborator

Statistics & Data Corporation

INDUSTRY

collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Andover Eye Associates

INDUSTRY

NCT04296864 - Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC) | Biotech Hunter | Biotech Hunter